Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by B. Guler
Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pcn140 - Cost-Effectiveness Analysis of Alectinib vs Crizotinib in First Line Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of ALK Testing and First-Line Crizotinib Therapy for Non-Small-Cell Lung Cancer in China
PLoS ONE
Multidisciplinary
Budget Impact of Alectinib in the Treatment of Naïve Anaplastic Lymphoma Kinase-Positive (ALK+) Advanced Non-Small Cell Lung Cancer (NSCLC) in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
Clinical Cancer Research
Cancer Research
Oncology
How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer
Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy
BMJ Open
Medicine
